Physician profile
Beatrice A Denefield
NPI 1962450619
$2,307.89
in general payments reported to CMS, 2019-2025
12 companies · $25.99 in 2025
The $25.99 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $156 · 2021: $220 · 2022: $401 · 2023: $791 · 2024: $223 · 2025: $25.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $686.31 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $353.12 | 2022-2024 | Ingrezza |
| Abbvie INC. | $338.62 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $205.02 | 2019-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Allergan, INC. | $194.41 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Corium, LLC | $124.74 | 2022 | |
| Sunovion Pharmaceuticals INC. | $115.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $93.15 | 2020-2025 | Invega Sustenna |
| Indivior INC. | $29.83 | 2024 | Sublocade |
| Lundbeck LLC | $27.45 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatrice Denefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.